Antigens & Antibodies for Diagnostic Kit Development
  
     Committed to high sensitivity & specificity

The diagnosis of SARS-CoV-2 infection is central to the management of viral transmission. To affirm infection, precise diagnostic tests that detect viral nucleic acids, viral antigens or serological antibodies are required. Compared with nucleic acid tests, antigen or serological antibody tests are set up for rapid screening and instant detection for their convenience to perform and the short time required for generating test results.

Rapid and accurate viral detection is the starting point to contain the COVID-19 pandemic.

Antigen tests that detect the presence of virus in nasopharyngeal fluids are used to prevent infectious spread between persons and communities. The challenge of diagnosis has upgraded due to the increasing number of cases of asymptomatic infection, which may aid inadvertent spread of the virus to others. Therefore, high test sensitivity and specificity are required to minimize the chance of false-negative test results.

Inducing immunity against SARS-CoV-2 is the next frontier for COVID-19 control.

Serological antibody tests as the complement of virus detection can indicate past infection. In these tests, IgG, IgM and neutralizing antibodies are detected qualitatively by enzyme-linked immunosorbent assay (ELISA). Serological antibody tests are helpful to assess protection against subsequent viral exposure, trace contact, and perform broad epidemiological evaluations.

The war against SARS-CoV-2 has changed because of mutants.

From D614G to Delta and Lambda, mutants have replaced the wild type and changed the war against COVID-19. Consequently, effectiveness of the existing detection methods, which were developed based on the parental type of the virus, becomes a significant question. Minimizing off-target effects becomes the key to block the spread of viral mutants.

TThe sensitivity and specificity of diagnostic kits significantly depend on the quality of the antigen or antibody reagents. To support the development of SARS-CoV-2 diagnostic tools, ACROBiosystems supply a collection of high-quality mutants-specific antigens and antibody reagents with verified high purity, bioactivity and batch-to-batch consistency.

The matched SARS-CoV-2 S/N antibody pairs are specifically designed for antigen detection kit development, which are suitable for a diverse set of applications, including ELISA, Chemiluminescence immunoassay (CLIA), Gold Immunochromatography Assay (GICA), etc. These antibody pairs are characterized with high sensitivity, specificity and consistency for antigen detection of both the wild type antigen and VOC mutants.

Product list

These antibodies were recommended for antigen detection by double antibody sandwich.

>>>  Virus lysis buffer (Cat.No. LY-14) is available for antigen detection kit development.

>>>  If you have any bulk order inquiry, please feel free to click here.

Anti-nucleocapsid antibody pair NUN-CH14/NUN-CH15

Detection of multiple mutants (Delta, Lambda, etc.)

The antibody pair NUN-CH14/NUN-CH15 can detect multiple nucleocapsid mutants (Alpha, Beta, Gamma, Kappa, Delta, Lambda) at comparable sensitivity with the wild type antigen (<2 ng/mL) in sandwich GICA.

High sensitivity verified by inactivated virus sample and antigens

The two antibodies (NUN-CH14/NUN-CH15) bind at different epitopes of the SARS-CoV-2 nucleocapsid protein, significantly improving the efficiency of antigen detection. The antibody pairs can detect the inactivated virus sample at 1:38400 dilution ratio, as well as the Delta variant and wild type antigens at both 0.195 ng/mL.

The detection results of the inactivated virus sample at gradient dilution ratio

The detection results of the Delta and wild type antigens at gradient concentrations.

High specificity for SARS-CoV-2

The antibody pair NUN-CH14/NUN-CH15 has no cross-reactivity with the other 5 human-infecting coronaviruses (HCoV-OC43, HCoV-HKU1, HCoV-229E, HCoV-NL63, MERS) except SARS, which has over 90% homologous genes with the SARS-CoV-2 nucleocapsid protein.

ACROBiosystems provide Spike and Nucleocapsid antigens and antibodies specifically designed for IgG/IgM antibody titer test development and compatible with multiple platforms, i.e. ELISA, Chemiluminescence immunoassay (CLIA), Gold Immunochromatography Assay (GICA). The products below are available in bulk order or customized size.

Product list

>>>  If you have any bulk order inquiry, please feel free to click here.

>>>  If you have any custom inquiries or suggestions for SARS-CoV-2 (COVID-19) related products, please click here.

Assay data

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 NP Antibody, Rabbit MAb (CLN27) with a linear range of 0.02-0.3 ng/mL (QC tested).

Protocol

Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. S1N-M122) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7 | Alpha, B.1.351 | Beta, P.1 | Gamma, B.1.617.1 | Kappa, B.1.617.2 | Delta mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.

Protocol

Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. S1N-M122) has high batch-to-batch consistency (%RSD<5%)

Protocol